Most hepatocellular carcinomas (HCCs) develop in a chronically injured liver, yet the extent to which this microenvironment promotes neoplastic transformation or influences selective pressures for genetic drivers of HCC remains unclear. We sought to determine the impact of hepatic injury in an established mouse model of HCC induced by Sleeping Beauty transposon mutagenesis. Chemically induced chronic liver injury dramatically increased tumor penetrance and significantly altered driver mutation profiles, likely reflecting distinct selective pressures. In addition to established human HCC genes and pathways, we identified several injury-associated candidates that represent promising loci for further study. Among them, we found that FIGN is overexpressed in human HCC and promotes hepatocyte invasion. We also validated Gli2's oncogenic potential in vivo, providing direct evidence that Hedgehog signaling can drive liver tumorigenesis in the context of chronic injury. Finally, we show that a subset of injury-associated candidate genes identifies two distinct classes of human HCCs. Further analysis of these two subclasses revealed significant trends among common molecular classification schemes of HCC. The genes and mechanisms identified here provide functional insights into the origin of HCC in a chronic liver damage environment. Conclusion: A chronically damaged liver microenvironment influences the genetic mechanisms that drive hepatocarcinogenesis. (HEPATOLOGY 2018;67:924-939) 
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Most hepatocellular carcinomas (HCCs) develop in a chronically injured liver, yet the extent to which this microenvironment promotes neoplastic transformation or influences selective pressures for genetic drivers of HCC remains unclear. We sought to determine the impact of hepatic injury in an established mouse model of HCC induced by Sleeping Beauty transposon mutagenesis. Chemically induced chronic liver injury dramatically increased tumor penetrance and significantly altered driver mutation profiles, likely reflecting distinct selective pressures. In addition to established human HCC genes and pathways, we identified several injury-associated candidates that represent promising loci for further study. Among them, we found that FIGN is overexpressed in human HCC and promotes hepatocyte invasion. We also validated Gli2's oncogenic potential in vivo, providing direct evidence that Hedgehog signaling can drive liver tumorigenesis in the context of chronic injury. Finally, we show that a subset of injury-associated candidate genes identifies two distinct classes of human HCCs. Further analysis of these two subclasses revealed significant trends among common molecular classification schemes of HCC. The genes and mechanisms identified here provide functional insights into the origin of HCC in a chronic liver damage environment. Conclusion: A chronically damaged liver microenvironment influences the genetic mechanisms that drive hepatocarcinogenesis. (HEPATOLOGY 2018;67:924-939) E ach year 745,000 people worldwide die from liver cancer, making it the second-leading cause of cancer-related death.
(1) Hepatocellular carcinoma (HCC) accounts for > 80% of cases, generally occurring in patients with chronic liver injury (CLI). (2) This condition typically includes sustained inflammation, compensatory hepatocyte proliferation, and fibrosis-an accumulation of extracellular matrix (ECM) that displaces parenchymal cells and increases liver stiffness. Induction of fibrosis, which is essentially scarring of the liver, represents a wound-healing response. Although acute injury can activate inflammation and mechanisms of fibrogenesis, a sustained stimulus is required for significant ECM accumulation and longterm damage to occur. All of the major risk factors for HCC, which include hepatitis B (HBV) or C virus (HCV) infection, alcohol-induced liver damage, and nonalcoholic fatty liver disease (NAFLD), provide a chronic injury stimulus that leads to significant hepatic inflammation and fibrosis. Without resolution of the underlying injury stimulus, liver fibrosis (LF) progressively increases in severity and can eventually lead to cirrhosis. One third of patients with cirrhosis will develop HCC in their lifetime, with an annual risk of 4%. (3) A strong association between LF and HCC is clear, given that 90% of cases develop in this context. (4) Abbreviations:: CIS, Common Insertion Site; CLI, chronic liver injury; ECM, extracellular matrix; HBsAg, HBV surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCG, hepatocarcinogenesis; HCV, hepatitis C virus; HGF, hepatocyte growth factor; Hh, hedgehog; HSCs, hepatic stellate cells; LF, liver fibrosis; NAFLD, nonalcoholic fatty liver disease; RNA-Seq, RNA-sequencing; SB, Sleeping Beauty.
Although this association has been recognized for decades, the extent to which fibrosis directly contributes to HCC pathogenesis remains unclear. Whether the two conditions co-occur because of shared etiologies or a direct role for fibrosis in promoting HCC is a question without a conclusive answer. Several potential fibrosis-dependent mechanisms of hepatocarcinogenesis (HCG) have been proposed (including enhanced mitogenic and antiapoptotic signaling through integrins, growth factor secretion by activated hepatic stellate cells (HSCs), increased stromal stiffness leading to proliferation, and growth factor sequestration by the ECM resulting in autocrine and paracrine signaling (5) ), but they require definitive experimental validation. It is also unclear how nascent HCC responds to the fibrotic microenvironment once initiated. Assessing the relative importance of fibrosis and other chronic injury-associated conditions during HCC development and progression has great potential to identify molecular pathways that may be targeted prophylactically in patients to prevent or delay HCC.
Modeling cancer in mice is an effective way to improve understanding of the molecular drivers of human disease. When engineering such models, it is essential to recapitulate the pathogenesis of human disease as closely as possible to maximize the relevance and utility of experimental findings. (6) Insertional mutagenesis screens using the Sleeping Beauty (SB) transposon system mimic the random, step-wise accumulation of somatic mutations that occurs in human cancer and are thus useful for cancer gene discovery. (7) We present here the results of a liver-specific SB mutagenesis screen conducted in the presence or absence of chronic hepatic injury induced by CCl 4 . Unlike most mouse models of HCC, our SB-induced model takes into account the damaged microenvironmental context in which the majority of human HCC cases develop.
By comparing transposon insertion profiles between tumors developed in normal or damaged livers, we have identified several mutation events that are subject to differential selective pressure depending on the microenvironmental context. Encouragingly, genes known to be involved in human HCC (Hippo, hepatocyte growth factor [HGF] , and WNT pathway members) were commonly mutated in injuryassociated tumors. This result highlights the relevance of our model to human cancer and supports the hypothesis that other recurrently mutated genes, including Gli2 and Fign, may be similarly relevant cancer genes.
Materials and Methods

MICE
Alb-Cre
Tg/Tg mice (8) (The Jackson Laboratory, Bar Harbor, ME) were crossed to RosaSBase LsL/LsL ;T2/ Onc3
Tg/Tg mice (TG12740 or TG12775 strain, which contain 11 or 28 transposon copies on Chr9 or Chr12, respectively) (9) to induce HCC. Control cohort tumors from previous SB screens (9, 10) were generated by crossing T2/Onc3
Tg/Tg strains to mice ubiquitously expressing SBase from the ROSA26 locus. (11) Male offspring were aged up to 65 weeks and monitored for liver tumor development. Starting at 8 weeks of age, mice received intraperitoneal injections of 10% CCl 4 in mineral oil (2.5 lL/g body weight twice a week for 12 weeks). Hydrodynamic tail vein injection and liver repopulation in Fah-deficient mice were performed as described. (12) All animal studies were conducted using procedures approved and monitored by the Institutional Animal Care and Use Committees at the University of Iowa (Iowa City, IA) and University of Minnesota (Minneapolis, MN).
ARTICLE INFORMATION:
CANDIDATE GENE COMPARISON ACROSS SB-INDUCED HCC MODELS
Candidates from five previously reported SBinduced HCC models (12) (13) (14) (15) (16) were compared. To normalize candidate-calling stringency across screens, gene lists from two studies (15, 16) were filtered based on criteria used in one of the studies (15) to identify "trunk" drivers (requiring at least four sequencing reads to include an insertion site in the Common Insertion Site [CIS] analysis). The R package, UpSet, (17) was used to generate a figure depicting overlaps.
IMMUNOHISTOCHEMISTRY
Antigen unmasking was performed with citrate buffer (pH 6), endogenous peroxidase was quenched with 3% H 2 O 2 , and 2.5% horse serum was used to block nonspecific staining. Sections were incubated with 1:100 dilutions of goat anti-GLI2 (AF3635-SP; Novus, Littleton, CO) or rabbit anti-FIGN (SAB1304554; Sigma-Aldrich, St. Louis, MO) overnight at 4˚C. Secondary antibodies: Vector Laboratories (Burlingame, CA) ImPRESS anti-goat (GLI2) or anti-rabbit (FIGN). Slides were developed with the Vector Laboratories NovaRED substrate reagent mix for 7 minutes and counterstained with hematoxylin. For the liver tissue microarray, each sample was assigned an intensity value for hepatocyte FIGN staining in a blinded manner: 4 5 strong cytoplasmic staining; 3 5 reduced cytoplasmic staining; 2 5 faint, discontinuous staining; and 1 5 essentially absent staining.
COMPARISON TO HUMAN HCC
Human HCC expression data for all orthologues of injury-associated driver genes were obtained through the LIHC project within The Cancer Genome Atlas (n 5 371). RSEM values were log 2 -transformed, a 1.5-SD cutoff was applied, and mean centering of both genes and tumors was performed. Next, k-means clustering (k 5 2) was used to identify two subtypes of human HCC based on expression of injury-associated candidates. Correlations were identified between these subtypes and selected clinical and molecular categories recently described. (18) A chi-squared test was performed to compare the category distribution within each injury-associated subtype to the entire HCC population.
Results
CLI INCREASES SEVERITY OF SB-INDUCED HCC
A model of spontaneous HCC was produced using mice with liver-specific SB mutagenesis (RosaS Base
Tg/1 , Alb-Cre
). (8, 9) Only males were aged to assess tumor formation, because a similar SB HCC model reported tumor resistance in females. (14) Starting at 8 weeks of age, CLI was induced in half (n 5 77) of the mutagenized cohort by intraperitoneal injection of CCl 4 twice-weekly for 12 weeks. Injected and control untreated mice (n 5 77) were aged to 65 weeks or until moribund. Histological analysis by Masson's trichrome staining revealed persistent LF at the time of euthanasia for all analyzed CCl 4 -treated mice (Supporting Table S1 ; Supporting Fig. S1 ). Over 95% of tumors from CCl 4 -treated animals evaluated by histopathology were clearly HCC (23 of 24), as expected.
Induction of CLI with CCl 4 increased tumor penetrance and multiplicity, while decreasing latency (Fig.  1 ). All CCl 4 -treated mice developed liver tumors, with an average latency of 48.5 weeks. Only 44% of control mice developed tumors within the 65-week aging period, with an average latency of 64.5 weeks. Of the mice that developed HCC, average multiplicities of 5.0 and 1.7 tumors per mouse were observed for the CCl 4 -treated and control cohorts, respectively, with slight differences between the two SB transposon strains used. A control cohort (n 5 17) lacking SBinduced mutagenesis (Cre-negative) was subjected to CCl 4 -induced liver damage to estimate the frequency of spontaneous tumors in this context. When euthanized at 65 weeks of age, only 10 liver tumors were collected from 3 of the mice (18%).
DAMAGED LIVER MICROENVIRONMENT INFLUENCES MUTATION PROFILE IN SB-INDUCED HCCs
To identify recurrent mutation events implicated as drivers of HCG, transposon integration sites were profiled in 343 and 55 liver tumors induced in the presence or absence of CCl 4 -induced hepatic injury, respectively. To increase the statistical power in detecting differences in driver mutation frequency between the two cohorts, the control cohort was expanded using 42 liver tumors (total, n 5 97) generated by two previous SB screens. (9, 10) Absence of hepatic fibrosis in each group of untreated SB-mutagenized liver tumors was verified before downstream analysis. DNA fragments containing transposon/genome junctions were amplified by ligation-mediated PCR and sequenced using the Illumina HiSeq platform. A list of clonal integration sites was generated for each sample based on criteria including relative abundance within the sample. (19) Only these clonally expanded sites were included in subsequent analyses, because they most confidently represent mutation events that have been subject to positive selection during tumor development and progression. A gene-centric CIS analysis (19) was performed for each cohort independently to identify genes with higher frequencies of transposon-induced mutation than predicted based on a random integration pattern. Table 1 lists the candidate driver genes mutated in 2% of tumors in either cohort that were preferentially mutated in one cohort and all driver genes common to both cohorts. Overall, we identified 419 and 49 candidate genes in injury-associated and control tumors, respectively (Supporting Tables S2 and S3) , with 21 genes implicated in both cohorts. Insertion within the Rtl1 locus was the most commonly observed event in both cohorts, consistent with its validated role as an oncogene (20) and with what we and others have observed. (9, 15) Additional genes mutated in >5% of tumors include Met, Fign, Gli2, and Dpyd in the CCl 4 cohort and Hras, Dpyd, Kras, Stag2, Snd1, Dennd5b, and Fndc3b in the untreated cohort.
Fisher's exact test was used to identify candidate driver genes significantly enriched for recurrent mutation in one cohort or the other (Table 1) . Met, Fign, and Gli2 mutations were significantly enriched in the CCl 4 cohort, whereas Hras and Dennd5 mutations were significantly more common in control tumors. Notably, Fign mutations were detected in 8% (27 of 343) of injury-associated tumors, but were never detected in control tumors. We identified three classes of driver genes based on relative abundance in tumors from each cohort: higher in the CCl 4 cohort, higher in the control cohort, and common to both cohorts. Figure 2 shows the distribution of driver mutations across these three classes for both tumor cohorts. Interestingly, tumors in the CCl 4 cohort with mutations in Fign or Gli2 had fewer driver gene mutations than other tumors (P 5 0.0022) (Supporting Fig. S2 ), suggesting that Fign and Gli2 mutations may be particularly strong drivers of hepatic transformation in a damaged microenvironment.
COMPARISON TO OTHER SB-INDUCED HCC MODELS
To increase functional understanding of the genetic mechanisms driving injury-associated tumors, we compared candidate genes from the CCl 4 cohort to those identified by other SB-induced HCC models 
conducted in a variety of genetic contexts (see Materials and Methods for details). Though limited by differences in sample numbers, sequencing methodologies, and bioinformatics strategies across studies, this analysis revealed some overlap with each of the previously reported HCC models (Fig. 3) . A major determinant of genetic similarity was the version of SB transposon utilized (T2/Onc3 vs. T2/Onc or T2/Onc2), indicating that the internal promoter (CAG or MSCV, respectively) strongly influences the transposon's mutagenic activity, consistent with previous results. (9) Additionally, we found substantial overlap with models of HBV-associated HCC. Overall, 14% (57 of 419) of injury-associated candidates were also reported by two recent SB screens in which HBV surface antigen (HBsAg) was expressed hepatically. (15, 16) An additional 35% (148 of 419) were identified in one of the HBV screens, bringing the total overlap with our chronic injury model to 49% of candidate genes. Of the genes mutated in 2% of CCl 4 -associated tumors, 88% (50 of 57) were also identified as candidates in HBV-associated tumors. Eight of these top candidates (Dpyd, Snd1, Adk, Zbtb20, Gsk3b, Psd3, Trip12, and Stard13) were drivers in more than half of the SBinduced HCC models, providing strong support for potentially broad roles in HCG.
Gli2 IS A STRONG DRIVER OF HCG IN VIVO
Hedgehog (Hh) signaling pathway activation has been proposed to contribute to human HCC. (21, 22) Although direct evidence for a functional role in hepatic transformation is scarce, several studies have detected strong, tumor-specific GLI2 expression in 60%-80% of HCC samples by immunohistochemistry. (23) (24) (25) Others have suggested a role of the Hh pathway and Gli2 in HCC, (24, 26) but there is no evidence that Gli2 overexpression itself is capable of initiating HCG. Given its high mutation rate in injury-associated SBinduced liver tumors, we hypothesized that Gli2 overexpression cooperates with CCl 4 -induced liver damage to initiate HCC. To test this hypothesis, mice with stable hepatic expression of Gli2 were generated by hydrodynamic tail vein injection and liver repopulation. A subset of these mice was subsequently treated with CCl 4 to induce CLI. At 150 days postinjection, all surviving untreated Gli2-expressing mice developed tumors, with an average of 39.5 per mouse (Gli2 vs. mCherry; analysis of variance, P < 0.0001; Fig. 4A ). As expected, CCl 4 treatment increased tumor multiplicity to 57.0 tumors/ mouse (Gli2 CCl 4 vs. Gli2 untreated; Tukey's post-hoc, P 5 0.006).
Unexpectedly, 89% of mice (59 of 66) receiving the Gli2 transgene died within 75 days of hydrodynamic injection without tumor formation. Morbidity in this cohort did not likely result from failure to rescue the Fah deficiency given that Fah transgene delivery was verified in a subset of animals by a luciferase reporter included in the transgene cassette. Lethality may instead result from interference of Gli2 overexpression with liver repopulation and/or function. We hypothesized that reducing the strong overexpression observed in livers of injected mice (Fig. 4D,E) by decreasing the amount of injected Gli2 transgene would eliminate lethality by producing a mosaic liver in which a smaller percentage of hepatocytes overexpress Gli2. A small cohort of mice was generated in which the Gli2 transgene was diluted 1:10 relative to the Fah transgene. As expected, all mice survived and developed spontaneous tumors, albeit with decreased multiplicity (Fig. 4F) . 
-
Whereas CCl 4 treatment significantly increased Gli2-mediated HCG in vivo, Gli2 overexpression alone produced an unexpectedly high tumor burden, perhaps in conflict with the results of our genetic screen (Fig. 2) . However, the hydrodynamic delivery model utilized for this experiment involves substantial hepatic injury, because the livers of Fah-null mice must regenerate from a small population of Fah 1 hepatocytes. (27) We also speculated that this process might impact endogenous Gli2 expression even in the absence of transgene expression. We performed Gli2 staining on liver sections from mice undergoing liver regeneration following hydrodynamic injection with a control plasmid expressing mCherry. Consistent with previous reports, (22) age-matched control mice did not detectably express Gli2 protein (Fig. 4B) . However, variable levels of Gli2 expression were apparent in hepatocytes of regenerating livers, indicating that endogenous Gli2 expression is activated during liver repopulation following damage (Fig. 4C) .
Fign IS OVEREXPRESSED IN REGENERATING LIVER AND HUMAN LIVER TUMORS
Fign was among the most common driver mutations in the CCl 4 -treated tumor cohort (Fig. 2) .
Interestingly, Fignl2 was identified as a driver in the same tumor cohort, although its mutation frequency was significantly lower (Supporting Table S2 ). The pattern of transposon insertions within these loci suggests that overexpression of Fign or Fignl2 can promote HCG in the context of liver injury. As with Gli2, Fign staining on sections from regenerating Fahnull mouse livers revealed moderate to strong expression in sporadic hepatocytes (Supporting Fig. S3 ), suggesting a potential role in this process.
RNA-sequencing (RNA-Seq) data from 371 human HCCs in The Cancer Genome Atlas indicate that 15% of human HCCs overexpress (z > 5 2.0) FIGN and/or FIGNL2 (Supporting Fig. S4A ). We also performed FIGN staining on a panel of 100 human HCC samples, evaluating four independent core biopsies from both tumor and normal adjacent liver for each patient (Supporting Fig. S4B-E) . Consistent with RNA-Seq results, 15% of human HCCs were found to have strong expression of FIGN protein at levels significantly higher than the normal matched tissue mouse hepatocyte cell line (TIB-73) had no effect on ploidy (Supporting Fig. S4F ) or proliferation rate in cells overexpressing Fign under either normal or lowserum conditions (data not shown).
A recent publication showed that Fign contributes to astrocyte migration by severing tyrosinated microtubules at the leading edge of the cell, (29) leading us to hypothesize that Fign overexpression increases hepatocyte invasion through ECM. We have previously shown that TIB-73 cells are capable of generating spheroids in Matrigel suspension cultures. (20) As expected, cells transfected with empty vector produced noninvasive spheroids in Matrigel after 1 week in culture (Fig. 5A,B) . In contrast, TIB-73 cells overexpressing Fign displayed a more invasive phenotype, exhibiting altered colony morphology with collective invasion into the Matrigel (Fig. 5C,D) . Fign overexpression also promoted invasion through Matrigel in response to an HGF gradient (Fig. 5E ).
COMPARISON TO HUMAN HCC
To assess the broader relevance of our model to human HCC, we analyzed expression of genes orthologous to injury-associated candidates from our screen in 371 human HCCs in The Cancer Genome Atlas LIHC project. Unsupervised k-means clustering identified a set of 24 genes that reliably segregated human HCCs into two groups that we designated injuryassociated subtypes 1 and 2 (Fig. 6A) . Interestingly, injury-associated subtype 1 is defined by elevated expression of a gene set that includes FIGN, FIGNL2, and GLI2-drivers specific to HCCs that emerged from our CCl 4 -treated cohort (Fig. 3) .
We next performed correlation analyses to identify clinical characteristics shared by tumors in the injuryassociated subtypes we identified. For these comparisons, we relied on a recent publication that described a comprehensive clinical and molecular analysis of 191 human HCCs. (18) We assessed correlation with 12 distinct parameters and discovered that three different gene expression classification schemes showed significant correlations among the injury-associated subtypes we identified ( Fig. 6B ; Supporting Table S4 ). Most compelling was the association between injuryassociated subtype 1 and a cholangiocarcinoma-like gene expression signature first identified by Woo et al. (30) Figure 6C shows the strong associations between the injury-associated subtypes we identified and different gene expression subtypes previously described.
Finally, we examined somatic mutation data from tumors within each injury-associated subtype for associations with recently reported HCC drivers. (18) Significant associations were observed between injuryassociated subtype 2 and mutations in TERT promoter (q 5 0.0003), CTNNB1 (q 5 0.003), and ALB (q 5 0.023), whereas BAP1 mutations were associated with injury-associated subtype 1 (q 5 0.006; Supporting Table S4 ). These observations suggest that our genetic screen identified genetic trends relevant for human HCC.
Discussion
We describe here a forward genetic mutagenesis screen conducted in HCCs developing in the presence or absence of CLI. This approach identified several candidate genes predicted to be involved in HCC development, many of which were differentially detected in tumors depending on the microenvironmental context. The list of putative liver cancer genes includes known effectors of human HCC, as well as other drivers that represent good candidates for further study.
Induction of CLI by CCl 4 administration greatly increased the severity of HCC resulting from SB insertional mutagenesis. We observed 100% tumor penetrance in the CCl 4 cohort, compared to 44% in the untreated cohort, and multiplicity was 3-fold higher with injury. Our power to identify even relatively rare injury-associated driver mutations was enhanced by the large number of tumors developed in this cohort (the largest SB screen conducted to date). Although 18% of CCl 4 -treated mice developed tumors in the absence of transposon mobilization, it is clear that SB mutagenesis is the primary driver of tumorigenesis in the model. Additionally, it should be noted that CCl 4 is not directly mutagenic when used in mouse studies (although indirect DNA damage from oxidative stress can occur), (31) so although background tumorigenesis is slightly increased by CCl 4 alone, our ability to identify driver mutations is unlikely to be significantly affected by the presence of chemically induced mutations. Based on the injury stimulus and induction of hepatocyte turnover provided by CCl 4 treatment, it may be expected that fewer mutations would be required to transform hepatocytes as compared to undamaged liver. This does not seem to be the case in our model, given that the average number of clonally expanded mutations per tumor did not significantly differ between CCl 4 -treated (23.8 clonal mutations) and untreated (19.5 clonal mutations) mice (P 5 0.34). This result is consistent with our assumption that CCl 4 provides a minimal mutagenic contribution to tumor development in the model.
We observed a striking degree of overlap between injury-associated driver mutations and drivers identified by HBV-associated, SB-induced HCC screens (15, 16) (Fig. 3 ). The mouse model utilized in these screens expresses HBsAg in the liver, leading to Table S4 ). (18) (C) A dot plot shows individual TCGA LIHC samples in each injuryassociated subtype. chronic inflammation and hepatocyte damage. Importantly, mice do not develop fibrosis. (15, 32) In contrast, CCl 4 treatment induces inflammation, cellular damage, steatosis, and fibrosis in mice. (33) We speculate that candidate genes shared by CCl 4 -and HBVassociated models of SB-induced HCC may reflect selective pressures for neoplastic transformation imparted by chronic hepatocyte damage and liver inflammation. In contrast, the top candidates identified in CCl 4 -associated, but not HBV-associated, tumors (Fign, Gli2, Nfe2, and Med13l) may represent strong drivers of tumorigenesis specifically in the context of LF.
Our detection of recurrent Met mutations preferentially in injury-associated HCCs makes intuitive sense. Inserted SB transposons clustered upstream of, and in the same transcriptional orientation as, the open reading frame, a pattern indicative of overexpression (Supporting Fig. S5 ). (20, 34) Importantly, the overexpressed Met protein is predicted to be full length (Supporting Fig. S6 ) and thus still dependent on HGF ligand binding for activation of its tyrosine kinase activity and downstream proliferative signaling pathways. In a basal state, there is little hepatic HGF/Met signaling, demonstrated by the fact that liver-specific knockout of Met produces no overt phenotype. (35) Under these conditions, a mutation resulting in overexpression of ligand-dependent Met would not be subject to strong positive selection. Upon induction of liver injury and fibrosis, HSCs are dramatically expanded and activated to secrete cytokines, including HGF. (36) In this environment, overexpressed Met would be functionally active, allowing it to promote tumorigenesis. CCl 4 treatment may thus provide a strong positive selective pressure for mutations causing Met overexpression.
Mutations predicted to drive Gli2 overexpression were also detected preferentially in injury-associated tumors. Gli2 is a transcription factor activated downstream of Hedgehog (Hh) signaling. The Hh pathway is activated in response to many types of liver injury, where it plays a role in regeneration. (37) Mutations causing Gli2 overexpression could uncouple activation of Hh pathway transcriptional targets from upstream receptor signaling. Such mutations may confer a particularly strong selective advantage in a liver environment with an initial injury stimulus to activate Hh signaling, preventing subsequent cessation of signaling and promoting increased fibrosis and eventual tumor development. Another possibility is that Gli2 activation may be strongly oncogenic in cell populations expanded during the liver's response to damage, but not in quiescent hepatocytes. These expanded populations include HSCs, myofibroblasts, and liver progenitors, cell types known to be highly responsive to Hh signaling and to contribute to both fibrotic and parenchymal mass in regenerated livers. (38, 39) Increased GLI2 protein expression and nuclear localization have been reported in human HCCs, particularly those with poor prognosis. (23, 25) Interestingly, a recent comprehensive molecular analysis of human HCCs identified an HBV insertion in the GLI2 promoter region associated with overexpression. (18) There is also evidence that other upstream signaling pathways, including epidermal growth factor and HGF, can increase GLI2-mediated transcription, (40) suggesting that GLI2 may represent a convergence point that integrates multiple upstream signaling pathways to drive proliferation during liver regeneration and transformation. Importantly, driver mutations in other Hh pathway genes (e.g., Smo, Ptch) were not identified in our screen, unlike other key pathways (e.g., Wnt, Hippo, and Met) from which multiple members were identified as drivers. This result suggests that GLI2 may function independently from canonical Hh signaling in HCC.
We also identified Fign as a candidate HCC oncogene. In addition to being a common driver in SB-induced tumors, we identified a substantial subset of human HCCs overexpressing FIGN at both the mRNA and protein levels. An independent transposon mutagenesis screen also identified Fign as a candidate oncogene in a mouse model of pancreatic cancer. (41) Interestingly, pancreatic tumors harboring Fign mutations exhibited hepatoid histology, suggesting potential shared etiological characteristics beyond simple histology between HCC and hepatoid adenocarcinomas. The mechanism of Fign-induced transformation may involve microtubule regulation. Although Fign overexpression did not affect ploidy in immortalized mouse hepatocytes (Supporting Fig.  S4F ), it did induce an invasive phenotype (Fig. 5) , consistent with Fign's reported role as a regulator of microtubule dynamics at the leading edge of the cell during astrocyte migration. (29) Additional experimentation is needed to determine whether Fign overexpression can drive transformation in chronically injured liver, perhaps through increased invasiveness that facilitates proliferation in a fibrotic microenvironment.
Our results demonstrate that CLI significantly influences the driver mutation profile in a mouse model of HCC. Similar influence likely exists in human HCC given the significant overlap between our injury-associated model and human tumors. We identified several candidate HCC driver mutations, with many subject to differential selection in tumors depending on microenvironmental context. Recurrently mutated genes include known effectors of human HCC and novel putative drivers that represent good candidates for further study. Our results provide some insight into the mechanistic role of injury and fibrogenesis in HCC, suggesting that oxidative stress and growth factor signaling from HSCs may be important mediators of fibrosis-associated HCG. Future studies could individually dissect contributions of fibrosis and other CCl 4 -induced liver injury phenotypes, including inflammation and hepatocyte proliferation, to HCC development.
This study presents direct evidence that Gli2 overexpression drives liver tumorigenesis in vivo. This result, combined with past observations of aberrant GLI2 staining in 80% of human tumors, (24, 25) suggests that GLI2 may be a common HCC driver. It is important to note that data from The Cancer Genome Atlas indicate that GLI2 expression in human HCC is not generally driven by direct mutation or copy number gain. Furthermore, GLI2 transcript is not overexpressed in tumors relative to normal adjacent liver samples (Supporting Fig. S7 ). We also did not detect increased Gli2 transcript during liver regeneration in the mouse Fah model (data not shown), despite observing increased protein expression (Fig. 4C,D) . These observations suggest that altered GLI2 protein stability may underlie elevated protein levels observed in human HCC.
Finally, we discovered that human HCCs can be categorized into two distinct subtypes based on expression of a subset of our injury-associated driver genes (Fig. 6A) . These subtypes have distinct molecular features, including mutation and expression profiles (Fig. 6B) . Interestingly, the strongest association we observed was between the CC-like class of HCC (30) and our injury-associated subtype 1 (P 5 1.83E-24), leading us to speculate that the injury-associated subtypes may have distinct cells of origin that are transformed by different mechanisms (Fig. 7) .
The injury-associated subtype 2 is enriched for many features commonly observed in HCC. It shows a typical sex bias of a 3:1 male-to-female ratio and frequent gain-of-function mutations in CTNNB1.
Mutations in ALB and TERT, recently described in HCC, (18) are also enriched in injury-associated subtype 2. These observations fit a model in which tumors originate from hepatocytes. Restored TERT expression would be necessary to maintain proliferation of a differentiated hepatocyte. Inactivation of ALB expression, which accounts for 20% of cellular RNA in normal hepatocytes, (42) would allow HCC to direct energy elsewhere and increase proliferation. (18) By contrast, HCCs in the injury-associated subtype 1 class have a cholangiocarcinoma-like gene expression pattern. (30) Tumors are not enriched for TERT or ALB mutations, suggesting that selective pressures differ from typical HCCs. Instead, tumors of this subtype overexpress FIGN, FIGNL2, and GLI2-genes that are unique drivers of our CCl 4 -treated mouse model of HCC (Figs. 2 and 3) . One possible explanation for these associations is that tumors emerge from progenitor cells expanded during CLI, such as those described by Tarlow et al. (43) Transformation of progenitors could involve mechanisms distinct from those necessary to transform differentiated hepatocytes. These differences in cell of origin could contribute to some of the variable associations and gene expression signatures described in human HCC.
Further study of the candidate driver genes and mechanisms we identified may provide diagnostic and therapeutic benefits for patients with HCC. In addition, experiments examining potential differences in cell of origin for injury-associated HCC could provide insights into more effective therapies that disrupt key mechanisms driving tumor progression. More work is needed to understand the biology underlying the injuryassociated driver mutations we report here. Nevertheless, we clearly show that selection of drivers during HCC initiation and/or progression is a complex process that is impacted by the liver microenvironment.
